Lane A, Scher N, Bhattacharjee S, Zlatic S, Roberts A, Gokhale A
bioRxiv. 2024; .
PMID: 39314281
PMC: 11419079.
DOI: 10.1101/2024.09.09.612106.
Lukac D, Machacova Z, Moudry P
Life Sci Alliance. 2022; 5(12).
PMID: 36260751
PMC: 9463495.
DOI: 10.26508/lsa.202201560.
Feliziani C, Fernandez M, Quassollo G, Holstein D, Bairo S, Paton J
Cell Calcium. 2022; 106:102622.
PMID: 35908318
PMC: 9982837.
DOI: 10.1016/j.ceca.2022.102622.
Minetti C, Remeta D, Hashimoto K, Bonala R, Chennamshetti R, Yin X
Life (Basel). 2022; 12(6).
PMID: 35743905
PMC: 9227171.
DOI: 10.3390/life12060872.
Valipour M
ACS Pharmacol Transl Sci. 2022; 5(6):387-399.
PMID: 35702393
PMC: 9159504.
DOI: 10.1021/acsptsci.2c00045.
Investigational antiviral drugs for the treatment of COVID-19 patients.
Beheshtirouy S, Khani E, Khiali S, Entezari-Maleki T
Arch Virol. 2022; 167(3):751-805.
PMID: 35138438
DOI: 10.1007/s00705-022-05368-z.
Recent advances in developing small-molecule inhibitors against SARS-CoV-2.
Xiang R, Yu Z, Wang Y, Wang L, Huo S, Li Y
Acta Pharm Sin B. 2021; 12(4):1591-1623.
PMID: 34249607
PMC: 8260826.
DOI: 10.1016/j.apsb.2021.06.016.
Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer.
Lee S, Jung J, Lee Y, Kim S, Kim J, Kim B
Cancers (Basel). 2021; 13(12).
PMID: 34203709
PMC: 8232331.
DOI: 10.3390/cancers13122987.
Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E.
Kumar R, Afsar M, Khandelwal N, Chander Y, Riyesh T, Dedar R
Antiviral Res. 2021; 189:105056.
PMID: 33711336
PMC: 7943376.
DOI: 10.1016/j.antiviral.2021.105056.
Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
Xu J, Xue Y, Zhou R, Shi P, Li H, Zhou J
Med Res Rev. 2020; 41(3):1375-1426.
PMID: 33277927
PMC: 8044022.
DOI: 10.1002/med.21763.
Emetine Is Not Ipecac: Considerations for Its Use as Treatment for SARS-CoV2.
Bleasel M, Peterson G
Pharmaceuticals (Basel). 2020; 13(12).
PMID: 33261173
PMC: 7760625.
DOI: 10.3390/ph13120428.
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.
Yousefi H, Mashouri L, Okpechi S, Alahari N, Alahari S
Biochem Pharmacol. 2020; 183:114296.
PMID: 33191206
PMC: 7581400.
DOI: 10.1016/j.bcp.2020.114296.
Biologically active isoquinoline alkaloids covering 2014-2018.
Shang X, Yang C, Morris-Natschke S, Li J, Yin X, Liu Y
Med Res Rev. 2020; 40(6):2212-2289.
PMID: 32729169
PMC: 7554109.
DOI: 10.1002/med.21703.
Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19.
Hassan S
Viruses. 2020; 12(4).
PMID: 32340120
PMC: 7232216.
DOI: 10.3390/v12040476.
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K
Antiviral Res. 2020; 178:104786.
PMID: 32251767
PMC: 7127386.
DOI: 10.1016/j.antiviral.2020.104786.
Lead Optimization of Dehydroemetine for Repositioned Use in Malaria.
Panwar P, Burusco K, Abubaker M, Matthews H, Gutnov A, Fernandez-Alvaro E
Antimicrob Agents Chemother. 2020; 64(4).
PMID: 31964796
PMC: 7179302.
DOI: 10.1128/AAC.01444-19.
The Trans Golgi Region is a Labile Intracellular Ca Store Sensitive to Emetine.
Gallegos-Gomez M, Greotti E, Lopez-Mendez M, Sanchez-Vazquez V, Arias J, Guerrero-Hernandez A
Sci Rep. 2018; 8(1):17143.
PMID: 30464185
PMC: 6249204.
DOI: 10.1038/s41598-018-35280-z.
mRNP architecture in translating and stress conditions reveals an ordered pathway of mRNP compaction.
Khong A, Parker R
J Cell Biol. 2018; 217(12):4124-4140.
PMID: 30322972
PMC: 6279387.
DOI: 10.1083/jcb.201806183.
Unexplored Molecular Features of the RNA Lariat Debranching Enzyme Dbr Expression Profile.
Valdes J, Ortuno-Pineda C, Saucedo-Cardenas O, Mendoza-Figueroa M
Front Cell Infect Microbiol. 2018; 8:228.
PMID: 30023353
PMC: 6039765.
DOI: 10.3389/fcimb.2018.00228.
Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: possible therapeutic approach for hyperoxaluria.
Belostotsky R, Lyakhovetsky R, Sherman M, Shkedy F, Tzvi-Behr S, Bar R
J Mol Med (Berl). 2018; 96(7):621-630.
PMID: 29777253
DOI: 10.1007/s00109-018-1651-8.